Impact of genetic polymorphism on response to antiviral treatment in patients with hepatitis C

Impact of genetic polymorphism on response to antiviral treatment in patients with hepatitis C - Impact of genetic polymorphism on response to antiviral treatment in patients with hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006888

Enrollment

3000

Registered

2011-12-28

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with hepatitis C or cirrhotic patients with HCV antibody-positive or HCV-RNA-positive.

Exclusion criteria

Exclusion criteria: 1) patients during pregnancy, during breast-feed, having a plan of pregnancy 2) patients with autoimmune disease 3) patients with malignant disease 4) patients with bleeding tendency (prothorombin time<50%, platelet count<30,000/mm3) 5) patients disqualified by principal investigator

Design outcomes

Primary

Measure	Time frame
1)elucidate the relation between ITPA polymorphism and effect of antiviral treatment 2)elucidate the relation between IL28B polymorphism and effect of antiviral treatment	—

Countries

Japan

Contacts

Public ContactYuki Tahata

Osaka University Graduate School of Medicine The department of Gastroenterology and Hepatology

yuki.tahata@gh.med.osaka-u.ac.jp06-6879-3621

Outcome results